11:47 AM EDT, 09/16/2025 (MT Newswires) -- The US Food and Drug Administration has issued a warning letter to Hims & Hers Health ( HIMS ) saying claims for the company's compounded semaglutide product on its website are misleading or false.

The letter, dated Sept. 9, says that "compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not."

Hims & Hers Health ( HIMS ) did not immediately reply to a request for comment by MT Newswires.

Shares of Hims were down 7.3% in recent trading.

Price: 50.09, Change: -3.87, Percent Change: -7.17